Dr. Weise Discusses Challenges With Biosimilar Acceptance in Oncology

Martina Weise, MD
Published: Thursday, Oct 25, 2018



Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses challenges with biosimilar acceptance in oncology.

When supportive care biosimilars entered the oncology landscape over 10 years ago, they were met with some skepticism, says Weise. This skepticism is echoed today, as biosimilars for biologics such as trastuzumab (Herceptin) and bevacizumab (Avastin) are awaiting use in the United States. As time has progressed, there has been more understanding as to the regulatory procedure for approving biosimilars, as well as the benefit that they offer.

Not only do biosimilars create competition in the marketplace, but they also offer the opportunity for patients in countries that cannot be offered biologics to receive care, says Weise. She adds that in Eastern European countries that previously had not had access to biologics are now experiencing an increase in the use of biosimilars for the support and treatment of patients with cancer.
SELECTED
LANGUAGE


Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses challenges with biosimilar acceptance in oncology.

When supportive care biosimilars entered the oncology landscape over 10 years ago, they were met with some skepticism, says Weise. This skepticism is echoed today, as biosimilars for biologics such as trastuzumab (Herceptin) and bevacizumab (Avastin) are awaiting use in the United States. As time has progressed, there has been more understanding as to the regulatory procedure for approving biosimilars, as well as the benefit that they offer.

Not only do biosimilars create competition in the marketplace, but they also offer the opportunity for patients in countries that cannot be offered biologics to receive care, says Weise. She adds that in Eastern European countries that previously had not had access to biologics are now experiencing an increase in the use of biosimilars for the support and treatment of patients with cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in CancerAug 30, 20201.5
Publication Bottom Border
Border Publication
x